Mirabegron (BioDeep_00000399155)
natural product
代谢物信息卡片
Mirabegron (YM178)
化学式: C21H24N4O2S (396.1619884)
中文名称: 米拉贝隆
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
InChI: InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
描述信息
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists
D000089162 - Genitourinary Agents > D064804 - Urological Agents
Mirabegron is a selective β3-adrenoceptor agonist with EC50 of 22.4 nM.
同义名列表
3 个代谢物同义名
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:65349
- KEGGdrug: D09535
- PubChem: 9865528
- DrugBank: DB08893
- ChEMBL: CHEMBL2095212
- CAS: 223673-61-8
- MoNA: CCMSLIB00000078618
- medchemexpress: HY-14773
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mahmoud M Kamal, Hanan S El-Abhar, Dalaal M Abdallah, Kawkab A Ahmed, Nour Eldin S Aly, Mostafa A Rabie. Mirabegron, dependent on β3-adrenergic receptor, alleviates mercuric chloride-induced kidney injury by reversing the impact on the inflammatory network, M1/M2 macrophages, and claudin-2.
International immunopharmacology.
2024 Jan; 126(?):111289. doi:
10.1016/j.intimp.2023.111289. [PMID: 38016347] - Iris Lim, Russ Chess-Williams. Mirabegron attenuates porcine ureteral contractility via α1-adrenoceptor antagonism.
Naunyn-Schmiedeberg's archives of pharmacology.
2022 07; 395(7):839-847. doi:
10.1007/s00210-022-02244-0. [PMID: 35445849] - Ru Huang, Alexander Tamalunas, Raphaela Waidelich, Frank Strittmatter, Christian G Stief, Martin Hennenberg. Inhibition of Full Smooth Muscle Contraction in Isolated Human Detrusor Tissues by Mirabegron Is Limited to Off-Target Inhibition of Neurogenic Contractions.
The Journal of pharmacology and experimental therapeutics.
2022 05; 381(2):176-187. doi:
10.1124/jpet.121.001029. [PMID: 35153197] - Thomas Halverson, Elizabeth R Mueller, Linda Brubaker, Alan J Wolfe. Symptom improvement with mirabegron treatment is associated with urobiome changes in adult women.
International urogynecology journal.
2022 05; 33(5):1319-1328. doi:
10.1007/s00192-022-05190-w. [PMID: 35412069] - Michelle Moughaizel, Elie Dagher, Nora Bouhsina, Valérie Lalanne, Chantal Thorin, Jean-Claude Desfontis, M Yassine Mallem. Effects of chronic mirabegron treatment on metabolic and cardiovascular parameters as well as on atherosclerotic lesions of WHHL rabbits with high-fructose high-fat diet-induced insulin resistance.
European journal of pharmacology.
2022 Apr; 921(?):174870. doi:
10.1016/j.ejphar.2022.174870. [PMID: 35257716] - Hiroshi Nakagomi, Takahiko Mitsui, Hiroshi Shimura, Tatsuya Ihara, Satoru Kira, Norifumi Sawada, Masayuki Takeda. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).
BMC urology.
2022 Mar; 22(1):40. doi:
10.1186/s12894-022-00989-7. [PMID: 35313873] - Kong Y Chen, Robert J Brychta, Nikita S Israni, Alex Jiang, Hannah J Lea, Taylor N Lentz, Anne E Pierce, Aaron M Cypess. Activating Human Adipose Tissue with the β3-Adrenergic Agonist Mirabegron.
Methods in molecular biology (Clifton, N.J.).
2022; 2448(?):83-96. doi:
10.1007/978-1-0716-2087-8_5. [PMID: 35167091] - Toshiro Suzuki, Tomonori Minagawa, Tetsuichi Saito, Tatsuo Nakagawa, Tomio Suzuki, Masayuki Furuhata, Kyoko Hosaka, Teruyuki Ogawa, Osamu Ishizuka. Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: A multicenter randomized trial.
International journal of urology : official journal of the Japanese Urological Association.
2021 Sep; 28(9):944-949. doi:
10.1111/iju.14608. [PMID: 34053119] - Zsuzsanna Z A Kovács, Gergő Szűcs, Marah Freiwan, Mónika G Kovács, Fanni M Márványkövi, Hoa Dinh, Andrea Siska, Katalin Farkas, Ferenc Kovács, András Kriston, Péter Horváth, Bence Kővári, Bálint Gábor Cserni, Gábor Cserni, Imre Földesi, Tamás Csont, Márta Sárközy. Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy.
Scientific reports.
2021 09; 11(1):17495. doi:
10.1038/s41598-021-96815-5. [PMID: 34471171] - I Glykas, Ch Fragkoulis, D D Mitsikostas, A Papatsoris, I Mitsogiannis, G Papadopoulos, A Skolarikos, I Gkialas, K Ntoumas, A Dellis. B3 agonists or anticholinergics in the treatment of the lower urinary tract dysfunction in patients with multiple sclerosis?-A randomized study.
World journal of urology.
2021 Aug; 39(8):3049-3056. doi:
10.1007/s00345-020-03555-8. [PMID: 33386947] - Mohamed G Soliman, Shawky A El-Abd, Ahmed M Tawfik, Mohamed H Radwan, Ahmed S El-Abd. Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO.
World journal of urology.
2021 Jun; 39(6):2049-2054. doi:
10.1007/s00345-020-03425-3. [PMID: 32869151] - Kelesitse Phiri, Jesper Hallas, Marie Linder, Andrea Margulis, Brandon Suehs, Alejandro Arana, Shahram Bahmanyar, Veena Hoffman, Cheryl Enger, Libby Horter, Ingvild Odsbu, Morten Olesen, Susana Perez-Gutthann, Nina Sahlertz Kristiansen, Kwame Appenteng, Stefan de Vogel, John Seeger. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.
Current medical research and opinion.
2021 05; 37(5):867-877. doi:
10.1080/03007995.2021.1891035. [PMID: 33591859] - Brian S Finlin, Hasiyet Memetimin, Beibei Zhu, Amy L Confides, Hemendra J Vekaria, Riham H El Khouli, Zachary R Johnson, Philip M Westgate, Jianzhong Chen, Andrew J Morris, Patrick G Sullivan, Esther E Dupont-Versteegden, Philip A Kern. Pioglitazone does not synergize with mirabegron to increase beige fat or further improve glucose metabolism.
JCI insight.
2021 03; 6(6):. doi:
10.1172/jci.insight.143650. [PMID: 33571166] - Jocelyn S Bel, T C Tai, Neelam Khaper, Simon J Lees. Mirabegron: The most promising adipose tissue beiging agent.
Physiological reports.
2021 03; 9(5):e14779. doi:
10.14814/phy2.14779. [PMID: 33650753] - Satoru Takahashi, Daisuke Kato, Hiromi Tabuchi, Satoshi Uno. Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study.
Lower urinary tract symptoms.
2021 Jan; 13(1):79-87. doi:
10.1111/luts.12335. [PMID: 32761776] - Prajakta Raut, Makarand Gambhire, Dhruvi Panchal, Vaishali Gambhire. Development and Optimization of Mirabegron Solid Lipid Nanoparticles as an Oral Drug Delivery for Overactive Bladder.
Pharmaceutical nanotechnology.
2021; 9(2):120-129. doi:
10.2174/2211738509666210127143107. [PMID: 33504321] - Mohamed G Soliman, Shawky El-Abd, Osama M El-Gamal, Ali Abdel Raheem, Ahmed R Abou-Ramadan, Ahmed S El-Abd. Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial.
Urologia internationalis.
2021; 105(11-12):1011-1017. doi:
10.1159/000515992. [PMID: 34010843] - Sung Yong Cho, Seong Jin Jeong, Sangchul Lee, Janghwan Kim, Seong Ho Lee, Min Soo Choo, Seung-June Oh. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study).
Neurourology and urodynamics.
2021 01; 40(1):286-294. doi:
10.1002/nau.24552. [PMID: 33389776] - Kimberly J Nahon, Laura G M Janssen, Aashley S D Sardjoe Mishre, Manu P Bilsen, Jari A van der Eijk, Kani Botani, Lisanne A Overduin, Jonatan R Ruiz, Jedrzej Burakiewicz, Oleh Dzyubachyk, Andrew G Webb, Hermien E Kan, Jimmy F P Berbée, Jan-Bert van Klinken, Ko Willems van Dijk, Michel van Weeghel, Frédéric M Vaz, Tamer Coskun, Ingrid M Jazet, Sander Kooijman, Borja Martinez-Tellez, Mariëtte R Boon, Patrick C N Rensen. The effect of mirabegron on energy expenditure and brown adipose tissue in healthy lean South Asian and Europid men.
Diabetes, obesity & metabolism.
2020 11; 22(11):2032-2044. doi:
10.1111/dom.14120. [PMID: 32558052] - Yuan C Shen, Hung J Wang, Wei C Lee, Chien H Chen, Yao C Chuang. Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder.
International journal of clinical practice.
2020 Sep; 74(9):e13537. doi:
10.1111/ijcp.13537. [PMID: 32438481] - Tsuyoshi Majima, Yoshihisa Matsukawa, Yasuhito Funahashi, Masashi Kato, Tokunori Yamamoto, Momokazu Gotoh. The effect of mirabegron on bladder blood flow in a rat model of bladder outlet obstruction.
World journal of urology.
2020 Aug; 38(8):2021-2027. doi:
10.1007/s00345-019-02939-9. [PMID: 31664511] - Alana E O'Mara, James W Johnson, Joyce D Linderman, Robert J Brychta, Suzanne McGehee, Laura A Fletcher, Yael A Fink, Devika Kapuria, Thomas M Cassimatis, Nathan Kelsey, Cheryl Cero, Zahraa Abdul Sater, Francesca Piccinini, Alison S Baskin, Brooks P Leitner, Hongyi Cai, Corina M Millo, William Dieckmann, Mary Walter, Norman B Javitt, Yaron Rotman, Peter J Walter, Marilyn Ader, Richard N Bergman, Peter Herscovitch, Kong Y Chen, Aaron M Cypess. Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity.
The Journal of clinical investigation.
2020 05; 130(5):2209-2219. doi:
10.1172/jci131126. [PMID: 31961826] - Bhavik Patel, Fernando Perez, Patrik Aronsson, Ranya Alothmani, Thomas Carlsson, Michael Winder. Combination drug therapy against OAB normalizes micturition parameters and increases the release of nitric oxide during chemically induced cystitis.
Pharmacology research & perspectives.
2020 02; 8(1):e00564. doi:
10.1002/prp2.564. [PMID: 32030913] - Christopher R Chapple, Francisco Cruz, Linda Cardozo, David Staskin, Sender Herschorn, Nurul Choudhury, Matthias Stoelzel, John Heesakkers, Emad Siddiqui. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
European urology.
2020 01; 77(1):119-128. doi:
10.1016/j.eururo.2019.09.024. [PMID: 31635815] - Kimio Sugaya, Saori Nishijima, Katsumi Kadekawa, Katsuhiko Noguchi, Tomoyuki Ueda, Hideyuki Yamamoto. Mirabegron causes vesical and urethral relaxation in rats with spinal cord injury.
Lower urinary tract symptoms.
2020 Jan; 12(1):92-98. doi:
10.1111/luts.12279. [PMID: 31389202] - Kamil Leis, Ewelina Mazur, Mariusz Racinowski, Wojciech Świerczyński, Aleksandra Baska, Przemysław Gałązka. Effect of Mirabegron on the Body's Exercise Capacity: A Review.
Endocrine, metabolic & immune disorders drug targets.
2020; 20(9):1448-1455. doi:
10.2174/1871530320666200516164434. [PMID: 32416711] - Shunye Su, Jinlei Lin, Liqin Liang, Ludong Liu, Zhipeng Chen, Yuan Gao. The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis.
Medicine.
2020 Jan; 99(4):e18802. doi:
10.1097/md.0000000000018802. [PMID: 31977871] - Kentaro Konishi, Tsuyoshi Minematsu, Yasuhisa Nagasaka, Kenji Tabata. Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase.
Xenobiotica; the fate of foreign compounds in biological systems.
2019 Aug; 49(8):912-921. doi:
10.1080/00498254.2018.1523489. [PMID: 30301385] - Lei Hao, Sheyenne Scott, Mehrnaz Abbasi, Yujiao Zu, Md Shahjalal Hossain Khan, Yang Yang, Dayong Wu, Ling Zhao, Shu Wang. Beneficial Metabolic Effects of Mirabegron In Vitro and in High-Fat Diet-Induced Obese Mice.
The Journal of pharmacology and experimental therapeutics.
2019 06; 369(3):419-427. doi:
10.1124/jpet.118.255778. [PMID: 30940691] - Wenhai Sui, Hongshi Li, Yunlong Yang, Xu Jing, Fei Xue, Jing Cheng, Mei Dong, Meng Zhang, Huazheng Pan, Yuguo Chen, Yunjian Zhang, Qingjun Zhou, Weiyun Shi, Xinsheng Wang, Han Zhang, Cheng Zhang, Yun Zhang, Yihai Cao. Bladder drug mirabegron exacerbates atherosclerosis through activation of brown fat-mediated lipolysis.
Proceedings of the National Academy of Sciences of the United States of America.
2019 05; 116(22):10937-10942. doi:
10.1073/pnas.1901655116. [PMID: 31085638] - Kentaro Konishi, Tsuyoshi Minematsu, Yasuhisa Nagasaka, Kenji Tabata. Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
Biopharmaceutics & drug disposition.
2019 May; 40(5-6):176-187. doi:
10.1002/bdd.2181. [PMID: 30985942] - John Meijer, Tom van den Berg, Robert Huls, Vincent Hofstede, Willem Niesing, Cas van den Beld, Walter Krauwinkel. Validation of LC-MS/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric population.
Journal of pharmaceutical and biomedical analysis.
2019 Apr; 167(?):155-160. doi:
10.1016/j.jpba.2019.02.007. [PMID: 30776753] - Tomohiro Matsuo, Yasuyoshi Miyata, Tatsufumi Nakamura, Katsuya Satoh, Hideki Sakai. Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy.
Lower urinary tract symptoms.
2019 Apr; 11(2):O65-O70. doi:
10.1111/luts.12218. [PMID: 29473309] - Sheng-Fu Chen, Hann-Chorng Kuo. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases.
Lower urinary tract symptoms.
2019 Apr; 11(2):O53-O58. doi:
10.1111/luts.12215. [PMID: 29380517] - Daisuke Kato, Hiromi Tabuchi, Satoshi Uno. Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study.
Lower urinary tract symptoms.
2019 Apr; 11(2):O152-O161. doi:
10.1111/luts.12237. [PMID: 30079630] - Yoshihisa Matsukawa, Shun Takai, Tsuyoshi Majima, Yasuhito Funahashi, Naoto Sassa, Masashi Kato, Tokunori Yamamoto, Momokazu Gotoh. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
Neurourology and urodynamics.
2019 03; 38(3):941-949. doi:
10.1002/nau.23935. [PMID: 30779375] - Lingdi Chen, Yu Zhang. Determination of Mirabegron in rat plasma by UPLC-MS/MS after oral and intravenous administration.
Revista da Associacao Medica Brasileira (1992).
2019 Feb; 65(2):141-148. doi:
10.1590/1806-9282.65.2.141. [PMID: 30892436] - Laurence Poekes, Justine Gillard, Geoffrey C Farrell, Yves Horsmans, Isabelle A Leclercq. Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis.
Laboratory investigation; a journal of technical methods and pathology.
2019 01; 99(1):4-16. doi:
10.1038/s41374-018-0120-x. [PMID: 30258096] - Hong-Goo Lee, Yun-Sang Park, Jin-Hyuk Jeong, Yong-Bin Kwon, Dae Hwan Shin, Ju-Young Kim, Yun-Seok Rhee, Eun-Seok Park, Dong-Wook Kim, Chun-Woong Park. Physicochemical properties and drug-release mechanisms of dual-release bilayer tablet containing mirabegron and fesoterodine fumarate.
Drug design, development and therapy.
2019; 13(?):2459-2474. doi:
10.2147/dddt.s212520. [PMID: 31413543] - Daisuke Kato, Hiromi Tabuchi, Satoshi Uno. Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study.
Lower urinary tract symptoms.
2019 Jan; 11(1):14-23. doi:
10.1111/luts.12188. [PMID: 28762672] - Jeff A Engle, Christina Fair. Sirolimus and mirabegron interaction in a hematopoietic cell transplant patient.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2018 Dec; 24(8):627-631. doi:
10.1177/1078155217726161. [PMID: 28814193] - Bum Sik Tae, Seok Cho, Byung Jo Jeon, Hoon Choi, Jae Young Park, Sung Yong Cho, Keon-Cheol Lee, Jae Hyun Bae. Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study.
BJU international.
2018 11; 122(5):866-872. doi:
10.1111/bju.14416. [PMID: 29802800] - Christian Gratzke, Rob van Maanen, Christopher Chapple, Paul Abrams, Sender Herschorn, Dudley Robinson, Arwin Ridder, Matthias Stoelzel, Asha Paireddy, Sang Jin Yoon, Salman Al-Shukri, Tomasz Rechberger, Elizabeth R Mueller. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
European urology.
2018 10; 74(4):501-509. doi:
10.1016/j.eururo.2018.05.005. [PMID: 29866467] - Alison S Baskin, Joyce D Linderman, Robert J Brychta, Suzanne McGehee, Esti Anflick-Chames, Cheryl Cero, James W Johnson, Alana E O'Mara, Laura A Fletcher, Brooks P Leitner, Courtney J Duckworth, Shan Huang, Hongyi Cai, H Martin Garraffo, Corina M Millo, William Dieckmann, Vladimir Tolstikov, Emily Y Chen, Fei Gao, Niven R Narain, Michael A Kiebish, Peter J Walter, Peter Herscovitch, Kong Y Chen, Aaron M Cypess. Regulation of Human Adipose Tissue Activation, Gallbladder Size, and Bile Acid Metabolism by a β3-Adrenergic Receptor Agonist.
Diabetes.
2018 10; 67(10):2113-2125. doi:
10.2337/db18-0462. [PMID: 29980535] - Yu Khun Lee, Hann-Chorng Kuo. Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities.
Geriatrics & gerontology international.
2018 Sep; 18(9):1330-1333. doi:
10.1111/ggi.13465. [PMID: 29931793] - Jan Krhut, Vladimír Borovička, Karolína Bílková, Radek Sýkora, David Míka, Jan Mokriš, Roman Zachoval. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study.
Neurourology and urodynamics.
2018 09; 37(7):2226-2233. doi:
10.1002/nau.23566. [PMID: 29603781] - Sheng-Mou Hsiao, Ting-Chen Chang, Chi-Hau Chen, Wen-Yih Wu, Ho-Hsiung Lin. Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study.
Lower urinary tract symptoms.
2018 Sep; 10(3):215-220. doi:
10.1111/luts.12167. [PMID: 28436145] - Brian S Finlin, Hasiyet Memetimin, Amy L Confides, Ildiko Kasza, Beibei Zhu, Hemendra J Vekaria, Brianna Harfmann, Kelly A Jones, Zachary R Johnson, Philip M Westgate, Caroline M Alexander, Patrick G Sullivan, Esther E Dupont-Versteegden, Philip A Kern. Human adipose beiging in response to cold and mirabegron.
JCI insight.
2018 08; 3(15):. doi:
10.1172/jci.insight.121510. [PMID: 30089732] - Kentaro Konishi, Daisuke Tenmizu, Shin Takusagawa. Identification of Uridine 5'-Diphosphate-Glucuronosyltransferases Responsible for the Glucuronidation of Mirabegron, a Potent and Selective β3-Adrenoceptor Agonist, in Human Liver Microsomes.
European journal of drug metabolism and pharmacokinetics.
2018 Jun; 43(3):301-309. doi:
10.1007/s13318-017-0450-x. [PMID: 29164523] - O Iatsyna, S Vernygorodskyi, F Kostyev. MORPHOLOGICAL ASSESSMENT OF NO-SYNTHASE DISTRIBUTION IN OVERACTIVE BLADDER AND STRESS URINE INCONTINENCE IN ANIMAL MODELS ADMINISTERED WITH EXPERIMENTAL PHARMACOCORRECTION REGIMENS.
Georgian medical news.
2018 Jun; ?(279):143-150. doi:
NULL. [PMID: 30035737] - Minoru Kobayashi, Akinori Nukui, Takao Kamai. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?.
Lower urinary tract symptoms.
2018 May; 10(2):158-166. doi:
10.1111/luts.12153. [PMID: 28009939] - Yumiko Nozawa, Daisuke Kato, Hiromi Tabuchi, Kentarou Kuroishi. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
Lower urinary tract symptoms.
2018 May; 10(2):122-130. doi:
10.1111/luts.12148. [PMID: 27860325] - Serena Milano, Andrea Gerbino, Giorgia Schena, Monica Carmosino, Maria Svelto, Giuseppe Procino. Human β3-Adrenoreceptor is Resistant to Agonist-Induced Desensitization in Renal Epithelial Cells.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology.
2018; 48(2):847-862. doi:
10.1159/000491916. [PMID: 30032151] - Marcel van Gelderen, Matthias Stölzel, John Meijer, Virginie Kerbusch, Christiane Collins, Cees Korstanje. An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-Induced Cardiovascular Effects.
Journal of clinical pharmacology.
2017 Dec; 57(12):1534-1544. doi:
10.1002/jcph.952. [PMID: 28618007] - Mike Herdman, Jameel Nazir, Zalmai Hakimi, Emad Siddiqui, Moses Huang, Marco Pavesi, Scott MacDiarmid, Marcus J Drake, Nancy Devlin. Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
The patient.
2017 Dec; 10(6):677-686. doi:
10.1007/s40271-017-0262-8. [PMID: 28646416] - Sender Herschorn, Christopher R Chapple, Paul Abrams, Salvador Arlandis, David Mitcheson, Kyu-Sung Lee, Arwin Ridder, Matthias Stoelzel, Asha Paireddy, Rob van Maanen, Dudley Robinson. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
BJU international.
2017 10; 120(4):562-575. doi:
10.1111/bju.13882. [PMID: 28418102] - Fabiano B Calmasini, Mariana G de Oliveira, Eduardo C Alexandre, Fábio H da Silva, Carmem P V da Silva, Tuany Z Candido, Edson Antunes, Fabíola Z Mónica. Long-term treatment with the beta-3 adrenoceptor agonist, mirabegron ameliorates detrusor overactivity and restores cyclic adenosine monophosphate (cAMP) levels in obese mice.
Neurourology and urodynamics.
2017 Aug; 36(6):1511-1518. doi:
10.1002/nau.23171. [PMID: 27794199] - Sandra M Bonilla-Becerra, Mariana G de Oliveira, Fabiano B Calmasini, Julio A Rojas-Moscoso, Angelina Zanesco, Edson Antunes. Micturition dysfunction in four-month old ovariectomized rats: Effects of testosterone replacement.
Life sciences.
2017 Jun; 179(?):120-129. doi:
10.1016/j.lfs.2017.05.006. [PMID: 28487215] - Fannie Morin, Anne-Sophie Blais, Geneviève Nadeau, Katherine Moore, Lucie Genois, Stéphane Bolduc. Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study.
The Journal of urology.
2017 04; 197(4):1158-1163. doi:
10.1016/j.juro.2016.11.101. [PMID: 27914999] - Nicolas Monjotin, Martine Farrié, Nathalie Vergnolle, Bruno Le Grand, James Gillespie, Didier Junquero. Bladder telemetry: A new approach to evaluate micturition behavior under physiological and inflammatory conditions.
Neurourology and urodynamics.
2017 02; 36(2):308-315. doi:
10.1002/nau.22970. [PMID: 26879122] - Helena Kopp Kallner, Caroline Elmér, Karl-Erik Andersson, Daniel Altman. Hormonal influence on the effect of mirabegron treatment for overactive bladder.
Menopause (New York, N.Y.).
2016 12; 23(12):1303-1306. doi:
10.1097/gme.0000000000000708. [PMID: 27529461] - Chun-Hou Liao, Hann-Chorng Kuo. High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment.
Medicine.
2016 Nov; 95(45):e4962. doi:
10.1097/md.0000000000004962. [PMID: 27828840] - Naoki Wada, Hiromichi Iuchi, Masafumi Kita, Kazumi Hashizume, Seiji Matsumoto, Hidehiro Kakizaki. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
Lower urinary tract symptoms.
2016 Sep; 8(3):171-6. doi:
10.1111/luts.12091. [PMID: 27619782] - Tomohiro Matsuo, Yasuyoshi Miyata, Katsura Kakoki, Miki Yuzuriha, Akihiro Asai, Kojiro Ohba, Hideki Sakai. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.
BMC urology.
2016 Jul; 16(1):45. doi:
10.1186/s12894-016-0165-3. [PMID: 27473059] - Anne-Sophie Blais, Geneviève Nadeau, Katherine Moore, Lucie Genois, Stéphane Bolduc. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
European urology.
2016 07; 70(1):9-13. doi:
10.1016/j.eururo.2016.02.007. [PMID: 26876327] - Scott D Edmondson, Cheng Zhu, Nam Fung Kar, Jerry Di Salvo, Hiroshi Nagabukuro, Beatrice Sacre-Salem, Karen Dingley, Richard Berger, Stephen D Goble, Gregori Morriello, Bart Harper, Christopher R Moyes, Dong-Ming Shen, Liping Wang, Richard Ball, Aileen Fitzmaurice, Tara Frenkl, Loise N Gichuru, Sookhee Ha, Amanda L Hurley, Nina Jochnowitz, Dorothy Levorse, Shruty Mistry, Randy R Miller, James Ormes, Gino M Salituro, Anthony Sanfiz, Andra S Stevenson, Katherine Villa, Beata Zamlynny, Stuart Green, Mary Struthers, Ann E Weber. Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.
Journal of medicinal chemistry.
2016 Jan; 59(2):609-23. doi:
10.1021/acs.jmedchem.5b01372. [PMID: 26709102] - Carlo Vecchioli Scaldazza, Carolina Morosetti. Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study.
Urologia internationalis.
2016; 97(3):325-329. doi:
10.1159/000445808. [PMID: 27092789] - NULL. mirabegron (BETMIGA⁰). Poorly effective in urge urinary incontinence.
Prescrire international.
2016 Jan; 25(167):8. doi:
NULL. [PMID: 26942249] - Sebastiaan C Goulooze, Adam F Cohen, Robert Rissmann. Mirabegron.
British journal of clinical pharmacology.
2015 Oct; 80(4):762-4. doi:
10.1111/bcp.12647. [PMID: 25819590] - Takahiro Maeda, Eiji Kikuchi, Masanori Hasegawa, Katsura Ishioka, Masayuki Hagiwara, Yasumasa Miyazaki, Toshiaki Shinojima, Akira Miyajima, Mototsugu Oya. Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia.
Urology.
2015 May; 85(5):1151-1155. doi:
10.1016/j.urology.2015.01.028. [PMID: 25770728] - Yoshihisa Matsukawa, Shun Takai, Yasuhito Funahashi, Tokunori Yamamoto, Momokazu Gotoh. Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder.
Urology.
2015 Apr; 85(4):786-90. doi:
10.1016/j.urology.2015.01.002. [PMID: 25709050] - Koji Ichihara, Naoya Masumori, Fumimasa Fukuta, Taiji Tsukamoto, Akihiko Iwasawa, Yoshinori Tanaka. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.
The Journal of urology.
2015 Mar; 193(3):921-6. doi:
10.1016/j.juro.2014.09.091. [PMID: 25254938] - Mário Angelo Claudino, Luiz Osório Silveira Leiria, Fábio Henrique da Silva, Eduardo Costa Alexandre, Andre Renno, Fabiola Zakia Mónica, Gilberto de Nucci, Kleber Yotsumoto Fertrin, Edson Antunes, Fernando Ferreira Costa, Carla Fernanda Franco-Penteado. Urinary Bladder Dysfunction in Transgenic Sickle Cell Disease Mice.
PloS one.
2015; 10(8):e0133996. doi:
10.1371/journal.pone.0133996. [PMID: 26241312] - Karl-Erik Andersson. The use of pharmacotherapy for male patients with urgency and stress incontinence.
Current opinion in urology.
2014 Nov; 24(6):571-7. doi:
10.1097/mou.0000000000000106. [PMID: 25144147] - Marcel van Gelderen, Reiner Tretter, John Meijer, Caroline Dorrepaal, Shanti Gangaram-Panday, Ashley Brooks, Walter Krauwinkel, James Dickinson. Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men.
International journal of clinical pharmacology and therapeutics.
2014 Aug; 52(8):693-701. doi:
10.5414/cp201979. [PMID: 24755125] - Koichiro Yuno, Yuko Onishi, Akihiro Arima, Kinuko Zaizen, Yoshinobu Aoki, Soichi Nakagawa, Marlowe J Schneidkraut, Yoichi Miyamae. Effect of mirabegron on plasma gonadotropic and steroidal hormone levels in rats after two weeks of oral administration.
The Journal of toxicological sciences.
2014 Jun; 39(3):507-14. doi:
10.2131/jts.39.507. [PMID: 24849685] - Osamu Yamaguchi, Eiji Marui, Hidehiro Kakizaki, Yukio Homma, Yasuhiko Igawa, Masayuki Takeda, Osamu Nishizawa, Momokazu Gotoh, Masaki Yoshida, Osamu Yokoyama, Narihito Seki, Yasushi Ikeda, Sumito Ohkawa. Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.
BJU international.
2014 Jun; 113(6):951-60. doi:
10.1111/bju.12649. [PMID: 24471907] - Walter Krauwinkel, James Dickinson, Marloes Schaddelee, John Meijer, Reiner Tretter, Jeroen van de Wetering, Gregory Strabach, Marcel van Gelderen. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
European journal of drug metabolism and pharmacokinetics.
2014 Mar; 39(1):43-52. doi:
10.1007/s13318-013-0133-1. [PMID: 23728524] - Hiromi Iitsuka, Tomoaki Tokuno, Yoko Amada, Hiroshi Matsushima, Masataka Katashima, Taiji Sawamoto, Shin Takusagawa, Marcel van Gelderen, Takanori Tanaka, Hideo Miyahara. Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies.
Clinical drug investigation.
2014 Jan; 34(1):27-35. doi:
10.1007/s40261-013-0146-1. [PMID: 24178236] - Toshiki Hatanaka, Masashi Ukai, Mai Watanabe, Akiyoshi Someya, Akiyoshi Ohtake, Masanori Suzuki, Koji Ueshima, Shuichi Sato, Noriyuki Masuda. Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys.
Naunyn-Schmiedeberg's archives of pharmacology.
2013 Nov; 386(11):1001-8. doi:
10.1007/s00210-013-0900-1. [PMID: 23832377] - Prajni Sadananda, Marcus J Drake, Julian F R Paton, Anthony E Pickering. A functional analysis of the influence of β3-adrenoceptors on the rat micturition cycle.
The Journal of pharmacology and experimental therapeutics.
2013 Nov; 347(2):506-15. doi:
10.1124/jpet.113.207340. [PMID: 24008334] - . Mirabegron for overactive bladder syndrome.
Drug and therapeutics bulletin.
2013 Aug; 51(8):90-2. doi:
10.1136/dtb.2013.8.0196. [PMID: 23949821] - Mark Sanford. Mirabegron: a review of its use in patients with overactive bladder syndrome.
Drugs.
2013 Jul; 73(11):1213-25. doi:
10.1007/s40265-013-0086-3. [PMID: 23818156] - Mahendra Kashyap, Pradeep Tyagi. The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option.
Expert opinion on drug metabolism & toxicology.
2013 May; 9(5):617-27. doi:
10.1517/17425255.2013.786700. [PMID: 23550899] - Jennifer Lee, Wenhui Zhang, Selina Moy, Donna Kowalski, Virginie Kerbusch, Marcel van Gelderen, Taiji Sawamoto, Nicole Grunenberg, James Keirns. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
Clinical therapeutics.
2013 Mar; 35(3):333-41. doi:
10.1016/j.clinthera.2013.02.014. [PMID: 23497763] - Hideo Otsuki, Takeo Kosaka, Kenzo Nakamura, Junnji Mishima, Yoshitaka Kuwahara, Takuji Tsukamoto. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.
International urology and nephrology.
2013 Feb; 45(1):53-60. doi:
10.1007/s11255-012-0343-5. [PMID: 23212147] - James Dickinson, Michaelene Lewand, Taiji Sawamoto, Walter Krauwinkel, Marloes Schaddelee, James Keirns, Virginie Kerbusch, Selina Moy, John Meijer, Donna Kowalski, Richard Morton, Kenneth Lasseter, Dennis Riff, Viera Kupčová, Marcel van Gelderen. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Clinical drug investigation.
2013 Jan; 33(1):11-23. doi:
10.1007/s40261-012-0031-3. [PMID: 23208320] - Toshiki Hatanaka, Masashi Ukai, Mai Watanabe, Akiyoshi Someya, Akiyoshi Ohtake, Masanori Suzuki, Koji Ueshima, Shuichi Sato, Seiji Kaku. Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats.
Naunyn-Schmiedeberg's archives of pharmacology.
2013 Jan; 386(1):71-8. doi:
10.1007/s00210-012-0814-3. [PMID: 23224420] - Shin Takusagawa, Aiji Miyashita, Takafumi Iwatsubo, Takashi Usui. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.
Xenobiotica; the fate of foreign compounds in biological systems.
2012 Dec; 42(12):1187-96. doi:
10.3109/00498254.2012.700140. [PMID: 22834478] - Charlotte Eltink, Jennifer Lee, Marloes Schaddelee, Wenhui Zhang, Virginie Kerbusch, John Meijer, Sjoerd van Marle, Nicole Grunenberg, Donna Kowalski, Ted Drogendijk, Selina Moy, Hiromi Iitsuka, Marcel van Gelderen, Hiroshi Matsushima, Taiji Sawamoto. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.
International journal of clinical pharmacology and therapeutics.
2012 Nov; 50(11):838-50. doi:
10.5414/cp201782. [PMID: 22943933] - Walter Krauwinkel, Jan van Dijk, Marloes Schaddelee, Charlotte Eltink, John Meijer, Grégory Strabach, Sjoerd van Marle, Virginie Kerbusch, Marcel van Gelderen. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Clinical therapeutics.
2012 Oct; 34(10):2144-60. doi:
10.1016/j.clinthera.2012.09.010. [PMID: 23063375] - Shin Takusagawa, Kanako Yajima, Aiji Miyashita, Shotaro Uehara, Takafumi Iwatsubo, Takashi Usui. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist.
Xenobiotica; the fate of foreign compounds in biological systems.
2012 Oct; 42(10):957-67. doi:
10.3109/00498254.2012.675095. [PMID: 22509825] - Shin Takusagawa, Jan Jaap van Lier, Katsuhiro Suzuki, Masanori Nagata, John Meijer, Walter Krauwinkel, Marloes Schaddelee, Mitsuhiro Sekiguchi, Aiji Miyashita, Takafumi Iwatsubo, Marcel van Gelderen, Takashi Usui. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Apr; 40(4):815-24. doi:
10.1124/dmd.111.043588. [PMID: 22269146] - Raymond van Teijlingen, John Meijer, Shin Takusagawa, Marcel van Gelderen, Cas van den Beld, Takashi Usui. Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 Mar; 887-888(?):102-11. doi:
10.1016/j.jchromb.2012.01.018. [PMID: 22317789] - Wim Vrydag, Astrid E Alewijnse, Martin C Michel. Do gene polymorphisms alone or in combination affect the function of human beta3-adrenoceptors?.
British journal of pharmacology.
2009 Jan; 156(1):127-34. doi:
10.1111/j.1476-5381.2008.00014.x. [PMID: 19133996]